

Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy

S. P. Finn · P. Smyth · S. Cahill · C. Streck ·
E. M. O'Regan · R. Flavin · J. Sherlock · D. Howells ·
R. Henfrey · M. Cullen · M. Toner · C. Timon ·
J. J. O'Leary · O. M. Sheils

Received: 27 July 2006 / Accepted: 2 November 2006 / Published online: 25 January 2007
© Springer-Verlag 2007

Abstract The most common sub-variant of papillary thyroid carcinoma (PTC) is the so-called follicular variant (FVPTC), which is a particularly problematic lesion and can be challenging from a diagnostic viewpoint even in resected lesions. Although fine needle aspiration cytology is very useful in the diagnosis of PTC, its accuracy and utility would be greatly facilitated by the development of specific markers for PTC and its common variants. We used the recently developed Applied Biosystems 1700 microarray system to interrogate a series of 11 benign thyroid lesions and conditions and 14 samples of PTC (six with classic

morphology and eight with follicular variant morphology). TaqMan® reverse transcriptase-polymerase chain reaction was used to validate the expression portfolios of 50 selected transcripts. Our data corroborates potential biomarkers previously identified in the literature, such as LGALS3, S100A11, LYN, BAX, and cluster of differentiation 44 (CD44). However, we have also identified numerous transcripts never previously implicated in thyroid carcinogenesis, and many of which are not represented on other microarray platforms. Diminished expression of metallothioneins featured strongly among these and suggests a possible role for this family as tumour suppressors in PTC. Fifteen transcripts were significantly associated with FVPTC morphology. Surprisingly, these genes were associated with an extremely narrow repertoire of functions, including the major histocompatibility complex and cathepsin families.

S. P. Finn · P. Smyth · S. Cahill · R. Flavin · J. J. O'Leary ·
O. M. Sheils
Department of Histopathology, University of Dublin,
Trinity College,
Dublin, Ireland

E. M. O'Regan · M. Toner
Dublin Dental School and Hospital,
Dublin, Ireland

C. Timon
Department of Otolaryngology, St. James's Hospital,
Dublin, Ireland

M. Cullen
Department of Endocrinology, St James's Hospital,
Dublin, Ireland

C. Streck · J. Sherlock · D. Howells · R. Henfrey
Applied Biosystems,
Foster City, CA, USA

O. M. Sheils (✉)
Department of Histopathology, Institute of Molecular Medicine,
Trinity Centre for Health Sciences, St. James's Hospital,
Dublin 8, Ireland
e-mail: osheils@tcd.ie

Keywords Papillary thyroid carcinoma · Biomarker ·
Follicular variant · Microarray · TaqMan® PCR

Introduction

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy and encompasses a variety of morphological/architectural variants, all of which are characterized by a distinctive nuclear appearance. In recent years, PTC has become an important paradigm of solid tumour molecular pathogenesis principally arising from intensive investigation prompted by the Chernobyl accident.

The discovery of ret rearrangements [12, 13, 35] and their association with radiation [42] was followed by the demonstration of the BRAF V600E mutation [21, 30]

found more commonly associated with sporadic PTC in non-radiation exposed populations [22, 32]. In the past, our group and others have noted an association between classic morphology and the BRAF V600E mutation and between variant morphology and ret rearrangements particularly ret/PTC-3 [11, 39]. Similarly ret/PTC-3 appears to strongly correlate with the solid/follicular variant seen commonly in children exposed to the Chernobyl fallout [42]. Nevertheless, the utility of these genetic lesions to diagnostic pathology and clinical practice has remained negligible.

Recently, gene expression microarray technology has been used to attempt to identify clinically relevant biomarkers of malignancy related to the thyroid [2, 6, 9, 10, 20, 28]. The discovery of such a biomarker or panel of biomarkers allied to the gold standard triage method of fine needle aspiration cytology (FNAC) would represent a significant advancement in the treatment of the solitary thyroid nodule.

An intriguing but commonly occurring variant of PTC is known as follicular variant (FVPTC). This lesion, which by definition retains the classic nuclear features of PTC, shows no evidence of the architectural papillae. FVPTC may be a controversial lesion due to interobserver variation in its pathological diagnosis [25]. Further, the occurrence of follicular patterned lesions with poorly or incompletely developed nuclear features may occur, which are easily dismissed as benign thyroid nodules. This has led to the controversial designation “well-differentiated tumour of uncertain malignant potential” for tumours of this type [45].

It is clear that this is a complex and contentious area, and that further work needs to be done to ascertain the underlying molecular biology of this particular variant. Recently, inroads into elucidation of molecular pathways underpinning PTC have been carried out using microarray studies. The overriding objective of these investigations was to identify clinically useful biomarkers. However, the majority of these studies have analysed PTC as though it were a homogenous singular entity without deference in a detailed manner to sub-variants and, in particular, the most common variant (FVPTC). The identification of specific biomarkers of FVPTC and a deeper understanding of its origins are clearly warranted.

The aim of this expression microarray study using a novel microarray platform was twofold: to identify markers that distinguish PTC from benign thyroid tissue and lesions and, secondly, to identify potential markers and further explore the molecular pathology of FVPTC.

Materials and methods

Patients and tissue samples

Tissue from 25 thyroid resections was collected prospectively from patients undergoing partial or total thyroidecto-

my for a variety of reasons at St. James’s Hospital, Dublin. The study had approval of the local ethics committee and informed consent was obtained from each patient by the clinical team before surgery. Small samples (<1 cm) were divided and immediately snap-frozen in liquid nitrogen for storage at -80°C until use. Histopathological examination of formalin-fixed paraffin-embedded sections was performed by two pathologists (SF and MT) for diagnostic categorisation. Classification of neoplastic tissue was made according to a recognised system [24]. The cohort comprised 11 benign lesions or conditions including follicular adenoma, nodular goitre, normal thyroid tissue, and Graves’s thyroiditis. The remaining 14 samples were diagnosed as PTC and comprised six classical morphology PTC and eight FVPTC (see Table 1). Immediately before RNA extraction, frozen sections were cut and stained to confirm the presence of representative lesional tissue with morphology corresponding to that noted in the diagnostic formalin-fixed paraffin-embedded sections.

RNA isolation and characterization

Samples were ground in liquid nitrogen and homogenised in RLT buffer (Qiagen, UK). RNA was then extracted using

Table 1 Sample cohort

Identifier	Diagnosis
N1	Normal thyroid tissue
N2	Normal thyroid tissue
N3	Lymphocytic thyroiditis
N4	Nodular hyperplasia
N5	Follicular adenoma
N6	Nodular hyperplasia with focal lymphocytic thyroiditis
N7	Nodular hyperplasia
N8	Follicular adenoma
N9	Nodular hyperplasia
N10	Follicular adenoma
N11	Grave’s thyroiditis
T1	Solid/FVPTC
T2	FVPTC
T3	PTC classic morphology
T4	FVPTC-oxyphil
T5	FVPTC
T6	FVPTC
T7	PTC classic morphology
T8	FVPTC
T9	PTC classic morphology
T10	FVPTC
T11	PTC classic morphology
T12	FVPTC
T13	PTC classic morphology
T14	PTC classic morphology

List of the 11 benign and 14 malignant lesions that were used in this study.

FV follicular variant; *PTC* papillary thyroid carcinoma

the RNeasy Mini Kit with optional on-column RNase-free DNase digestion (Qiagen) according to the manufacturer's instructions. RNA quantity was determined using UV spectrophotometry. RNA quality was assessed using the RNA 6000 Nano LabChip® Kit in conjunction with the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).

Microarray analysis

Applied Biosystems Human Genome Survey Arrays were used to analyse the transcriptional profiles of thyroid RNA samples in this study. Digoxigenin-UTP-labelled cRNA was generated and linearly amplified from 5 µg of total RNA using Applied Biosystems Chemiluminescent RT-IVT Labelling Kit v 2.0 using manufacturer's protocol. 10 µg of labelled cRNA were hybridized to each pre-hybridized microarray in a 1.5-ml volume at 55°C for 16 h. Array hybridization and chemiluminescence detection were performed using Applied Biosystems Chemiluminescence Detection Kit following manufacturer's protocol. Images were collected for each microarray using the 1700 analyser. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background and spot, and spatially normalized.

TaqMan® PCR validation

Sufficient RNA remained from 20 of the initial 25 samples for TaqMan® polymerase chain reaction (PCR) validation in a series of 50 targets. RNA was reverse transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, CA, USA). Primers and probes for TaqMan® PCR were obtained by using Applied Biosystems' pre-designed TaqMan® Gene Expression Assays. PCR was carried out using an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). Analysis of relative gene expression data was performed using the $\Delta\Delta\text{CT}$ method [23] with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control/reference assay.

Statistical analysis

Microarrays were analysed using Spotfire DecisionSite™ for Functional Genomics (Spotfire AB, Goteborg, Sweden) and R version 1.9.1, a free language and environment for statistical computing and graphics (R Development Core Team, 2004). Arrays were initially normalized, and genes were deemed undetectable and, therefore, excluded from final gene lists if they had a signal-to-noise ratio of less than three ($S/N < 3$) in greater than 18 of the 25 arrays.

An ANOVA test was used to generate p values for statistical differences between groups. Their p values were

then adjusted for multiple comparisons using the technique described by Benjamini and Yekutieli [3]. Genes were deemed statistically different between groups if they had an adjusted $p < 0.05$ and an average fold-change difference of greater than 2. Hierarchical clustering was performed based on the statistically different genes to determine whether samples grouped appropriately. Gene ontology analysis was performed using an online database known as the Panther classification system (<http://www.pantherdb.org>). Correlations between microarray and TaqMan® expression data were measured using the Pearson coefficient.

Results

Unsupervised clustering of all 25 samples demonstrated clustering into two major groups (data not shown) comprising the N group and the T group (see Table 1). There was no tendency for FVPTC to cluster independently with classic morphology PTC, confirming the close relationship of these variants of PTC. To identify potential markers of malignancy, ANOVA with false discovery rate correction was used to compare the benign and malignant thyroid cohorts. A p value cut-off of < 0.05 and fold-change difference of ≥ 2 yielded 236 statistically significant probes. Of these, 172 corresponded to fully annotated probes and are listed in Table 2.

Supervised hierarchical clustering was performed on the 25 arrays based on the 236 statistically significant probes to determine whether the samples would segregate appropriately. The resulting heat map can be observed in Fig. 1. Benign lesions and tumours clustered together with the exception of one tumour sample that clustered with the benign group (T5).

A binomial statistics tool was used to compare classifications of multiple clusters of lists to a reference list (i.e. the complete human genome) to statistically determine over- or under-representation of Panther classification categories. Biological processes over-represented in the up-regulated PTC cohort included tumour suppressor, oncogenesis, DNA replication, cell cycle, and cell adhesion ($p < 0.0001$). Genes involved in homeostasis and other homeostasis activities were highly over-represented in the down-regulated cohort ($p < 0.000001$).

ANOVA tests were used to determine which genes were differentially regulated in the FVPTC cohort only. Fifteen genes were identified, including cluster of differentiation 14 (CD14), CD74, CTSC, CTSH, CTSS, DPP6, ETHE1, human leucocyte antigen A (HLA-A), HLA-DMA, HLA-DPB1, HLA-DQB1, HLA-DRA, osteoclast stimulating factor 1 (OSTF1), TDO2, and a previously uncharacterized gene (noname).

Microarray results were validated using a reverse transcription reaction followed by TaqMan® PCR for 50 gene targets. The $\Delta\Delta\text{CT}$ method [23] was used to analyse

Table 2 Genes differentially expressed in malignant vs benign thyroid tissue

Gene Name	Gene Symbol	Adjusted <i>p</i> value	1700 probe ID
Genes up-regulated in malignant vs benign			
Active BCR-related gene	ABR	0.014482	154399
Adaptor-related protein complex 2, alpha 1 subunit	AP2A1	0.0312	115368
Apoptosis, caspase activation inhibitor	AVEN	0.030998	203738
BCL2-associated X protein	BAX	0.009782	146510
BH3 interacting domain death agonist	BID	0.021424	131216
Brain abundant, membrane attached signal protein 1	BASP1	0.024214	198318
Brain acyl-CoA hydrolase	BACH	0.014566	133876
Bromodomain adjacent to zinc finger domain, 1A	BAZ1A	0.03538	209809
Calcium/calmodulin-dependent protein kinase I	CAMK1	0.041887	157712
Cathepsin S	CTSS	0.046544	105790
CD44 antigen (homing function and Indian blood group system)	CD44	0.044181	133604
Chemokine (C-X-C motif) ligand 16	CXCL16	0.043234	199059
Chromosome 1 open reading frame 38	C1orf38	0.049072	202924
CLIP-170-related protein	CLIPR-59	0.023629	102205
Docking protein 1, 62 kDa (downstream of tyrosine kinase 1)	DOK1	0.041898	204989
Epidermodyplasia verruciformis 1	EVER1	0.003348	175569
FXYD domain containing ion transport regulator 5	FXYD5	0.01444	154607
FXYD domain containing ion transport regulator 5	FXYD5	0.023629	112771
Galactose-4-epimerase, UDP	GALE	0.047363	141143
Genethonin 1	GENX-3414	0.016836	124360
Hypothetical gene BC008967	BC008967	0.015683	108526
Hypothetical protein FLJ10849	FLJ10849	0.013822	224983
Hypothetical protein FLJ22531	FLJ22531	0.024391	145918
Hypothetical protein MGC4607	MGC4607	0.006507	211836
Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	ICAM1	0.028746	109070
Jun dimerization protein p21SNFT	SNFT	0.043301	144215
Lectin, galactoside-binding, soluble, 3 (galectin 3)	LGALS3	0.034491	179836
Major vault protein	MVP	0.0312	212354
Matrix metalloproteinase 14 (membrane-inserted)	MMP14	0.038682	152076
Milk fat globule-EGF factor 8 protein	MFGES	0.02392	144588
Mst3 and SOK1-related kinase	MST4	0.042028	112198
neuronal cell adhesion molecule	NRCAM	0.011178	106462
Phospholipase D3	PLD3	0.034491	143388
Promyelocytic leukemia	PML	0.016018	217558
Protein inhibitor of activated STAT protein PIASy	PIASY	0.00536	153434
Protein tyrosine phosphatase, receptor type, E	PTPRE	0.048653	221568
Rho GDP dissociation inhibitor (GDI) beta	ARHGDI3	0.043853	143589
S100 calcium binding protein A11 (calgizzarin)	S100A11	0.019933	145550
Similar to rat tricarboxylate carrier-like protein	BA108L7.2	0.025387	179870
SP110 nuclear body protein	SP110	0.0312	113484
Stimulated by retinoic acid gene 6	FLJ12541	0.043234	193986
Syndecan 3 (N-syndecan)	SDC3	0.048804	143980
Tax interaction protein 1	TIP-1	0.006673	119665
TBC1 domain family, member 2	TBC1D2	0.029907	205982
Tenascin C (hexabrachion)	TNC	0.032355	143831
Thymosin, beta 4, Y chromosome	TMSB4Y	0.040937	193911
Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)	TIMP1	0.032306	134692
Topoisomerase (DNA) II alpha 170 kDa	TOP2A	0.040937	135302
Transforming growth factor, beta 1	TGFB1	0.016836	170749
Transgelin 2	TAGLN2	0.031971	172296
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide	YWHAH	0.039009	188379
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	LYN	0.016175	194134

Table 2 (continued)

Gene Name	Gene Symbol	Adjusted <i>p</i> value	1700 probe ID
Genes down-regulated in malignant vs benign			
Aldehyde oxidase 1	AOX1	0.003227	106573
Ankyrin 2, neuronal	ANK2	0.035357	155780
Aspartate beta-hydroxylase	ASPH	0.002064	221656
Aspartate beta-hydroxylase	ASPH	0.019666	114180
ATPase, Cu ⁺⁺ transporting, beta polypeptide	ATP7B	0.044511	198852
Brain-specific protein p25 alpha	p25	0.023629	120622
Casein kinase	LOC149420	0.022382	149347
Cellular retinoic acid binding protein 1	CRABP1	0.008315	100295
Centromere protein J	CENPJ	0.0312	164563
Ceroid-lipofuscinosis, neuronal 5	CLN5	0.011021	205999
Chloride channel Kb	CLCNKB	0.040418	176266
Chondroitin beta1,4 <i>N</i> -acetylgalactosaminyltransferase	ChGn	0.013148	101140
Chromosome 11 open reading frame 8	C11orf8	0.001977	174025
Chromosome 11 open reading frame 8	C11orf8	0.004148	108279
Chromosome 21 open reading frame 4	C21orf4	0.0042	156895
Clusterin-like 1 (retinal)	CLUL1	0.019631	186062
Component of oligomeric golgi complex 3	COG3	0.003664	129212
Coxsackie virus and adenovirus receptor	CXADR	0.004648	108284
Crystallin, alpha B	CRYAB	0.030418	190274
Cytosolic sialic acid 9- <i>O</i> -acetyltransferase homolog	CSE-C	0.040993	213856
Dicarbonyl/ <i>L</i> -xylulose reductase	DCXR	0.001977	103350
DnaJ (Hsp40) homolog, subfamily B, member 4	DNAJB4	0.043853	103618
ERO1-like beta (<i>S. cerevisiae</i>)	ERO1LB	0.013962	207998
Extracellular link domain containing 1	XLKD1	0.039738	195865
Family with sequence similarity 13, member A1	FAM13A1	0.019631	116936
Fatty acid binding protein 4, adipocyte	FABP4	0.014832	150137
Fc fragment of IgG binding protein	FCGBP	0.001965	118361
Fibroblast growth factor receptor 2	FGFR2	0.0042	110548
FLJ35740 protein	FLJ35740	0.020224	101102
Friedreich ataxia region gene X123	X123	0.032602	133505
Glutamate-ammonia ligase (glutamine synthase)	GLUL	0.014649	175147
Glycine amidinotransferase (<i>L</i> -arginine/glycine amidinotransferase)	GATM	0.013962	111904
Glycoprotein M6A	GPM6A	0.011739	215326
Growth hormone receptor	GHR	0.017721	190306
HLA complex group 4	HCG4	0.025807	191199
Hypothetical protein BC009561	LOC119710	0.003227	211319
Hypothetical protein BC019238	LOC120379	0.013438	201200
Hypothetical protein FLJ13204	FLJ13204	0.003227	145066
Hypothetical protein FLJ13842	FLJ13842	0.016448	208504
Hypothetical protein FLJ14054	FLJ14054	0.049072	202017
Hypothetical protein FLJ20154	FLJ20154	0.014428	143310
Hypothetical protein FLJ20513	FLJ20513	0.019493	154130
Hypothetical protein FLJ32110	FLJ32110	0.015507	229492
Hypothetical protein FLJ32343	FLJ32343	0.012208	116902
Hypothetical protein FLJ33516	FLJ33516	0.03965	224600
Hypothetical protein FLJ37549	FLJ37549	0.001956	218577
Hypothetical protein FLJ39378	FLJ39378	0.005853	163223
Hypothetical protein FLJ40021	FLJ40021	0.023629	174198
Hypothetical protein LOC134285	LOC134285	0.018694	163671
Hypothetical protein MGC10946	MGC10946	0.022382	195982
Hypothetical protein MGC14425	MGC14425	0.015445	161569
Hypothetical protein MGC17299	MGC17299	0.026062	168452
Hypothetical protein MGC17943	MGC17943	0.0042	147296
Hypothetical protein MGC23980	MGC23980	0.018694	224619

Table 2 (continued)

Gene Name	Gene Symbol	Adjusted <i>p</i> value	1700 probe ID
Hypothetical protein MGC24047	MGC24047	0.001956	138122
Hypothetical protein MGC33607	MGC33607	0.033547	100645
Ionized calcium binding adapter molecule 2	IBA2	0.0042	179489
KIAA0390 gene product	KIAA0390	0.014832	119936
KIAA0703 gene product	KIAA0703	0.032602	146652
Lectin, mannose-binding, 1	LMAN1	0.031092	179632
Leiomodin 1 (smooth muscle)	LMOD1	0.022352	120404
Likely ortholog of rat SNF1/AMP-activated protein kinase	SNARK	0.044605	157942
LIM domain kinase 2	LIMK2	0.002409	151439
Low density lipoprotein-related protein 1B (deleted in tumors)	LRP1B	0.00536	209464
Low density lipoprotein-related protein 2	LRP2	0.040937	114919
Matrilin 2	MATN2	0.0042	167316
Metallothionein 1A (functional)	MT1A	0.013822	204773
Metallothionein 1A (functional) metallothionein 1E (functional) metallothionein 1K metallothionein 2A	MT1A MT2A MT1E MT1K	0.027037	146368
Metallothionein 1A (functional) metallothionein 1E (functional) metallothionein 2A metallothionein 1K	MT1A MT2A MT1K MT1E	0.043841	182305
Metallothionein 1A (functional) metallothionein 2A metallothionein 1K metallothionein 1E (functional)	MT1A MT1K MT1E MT2A	0.011739	223856
Metallothionein 1B (functional)	MT1B	0.019631	174119
Metallothionein 1F (functional)	MT1F	0.024726	144569
Metallothionein 1G	MT1G	0.0192	164525
Metallothionein 1G	MT1G	0.03965	171539
Metallothionein 1J	MT1J	0.008315	227956
Metallothionein 1X	MT1X	0.008335	119685
Metallothionein 1X	MT1X	0.010748	173072
Metallothionein IV	MT4	0.007447	223241
Methionine adenosyltransferase II, alpha	MAT2A	0.014428	158350
Mitogen-activated protein kinase 4	MAPK4	0.042306	131252
Myc-induced nuclear antigen, 53 kDa	MINA53	0.011959	130284
NIMA (never in mitosis gene a)- related kinase 11	NEK11	0.001965	194628
Otospiralin	LOC150677	0.018694	182360
PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10	PIST	0.013822	103651
Phospholipase A2 receptor 1, 180 kDa	PLA2R1	0.004029	134379
Phospholipase C-like 1	PLCL1	0.022657	206894
Phosphatidylinositol transfer protein, beta	PITPNB	0.014428	122698
Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1	PKHD1L1	0.0042	199896
Polymerase (DNA directed) iota	POLI	0.003227	167492
Potassium channel, subfamily K, member 9	KCNK9	0.000849	108648
Potassium channel-interacting protein 4	KCNIP4	0.011447	147058
Potassium inwardly-rectifying channel, subfamily J, member 13	KCNJ13	0.008972	124187
pp21 Homolog	LOC51186	0.004326	127636
Pre-B cell leukemia transcription factor 4	PBX4	0.030311	199118
Protein kinase, cAMP-dependent, catalytic, beta	PRKACB	0.023863	198878
Protein phosphatase 4, regulatory subunit 2 hypothetical protein LOC151987	PPP4R2 LOC151987	0.011338	200919
RAB23, member RAS oncogene family	RAB23	0.000659	122394
Ras association (RalGDS/AF-6) domain family 6	RASSF6	0.048804	119072
Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)	SGCD	0.011178	120415
Serum deprivation response (phosphatidylserine binding protein)	SDPR	0.011021	156433
SH3 and multiple ankyrin repeat domains 2	SHANK2	0.043996	193906
Solute carrier family 26, member 7	SLC26A7	0.0042	225067
Solute carrier family 26, member 7	SLC26A7	0.005853	213530
Solute carrier family 5 (iodide transporter), member 8	SLC5A8	0.031284	231731
SPARC related modular calcium binding 2	SMOC2	0.021505	135930
Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)	SDC2	0.001258	209676
Syntaxin 12	STX12	0.01117	199949

Table 2 (continued)

Gene Name	Gene Symbol	Adjusted <i>p</i> value	1700 probe ID
T-box 22	TBX22	0.024297	177517
Thioredoxin-like, 32 kDa	TXNL	0.001102	192552
Thyroid stimulating hormone receptor	TSHR	0.02176	108606
Tissue inhibitor of metalloproteinase 4	TIMP4	0.023629	184795
Trefoil factor 3 (intestinal)	TFF3	0.004648	114445
Trefoil factor 3 (intestinal)	TFF3	0.014428	100949
UDP- <i>N</i> -acetyl- α -D-galactosamine/polypeptide <i>N</i> -acetylgalactosaminyltransferase 9 (GalNAc-T9)	GALNT9	0.031284	161042
WEE1 homolog (<i>S. pombe</i>)	WEE1	0.024101	123533
WW domain containing oxidoreductase	WWOX	0.012208	224298
WW domain containing oxidoreductase	WWOX	0.024101	135080
Zinc finger protein 258	ZNF258	0.013962	225961
Zinc finger protein 36, C3H type-like 2	ZFP36L2	0.018837	210469

Two-tail ANOVA with *p* value correction yielded 173 probes (52 up-, 121 down-regulated in PTC) significantly different ($p < 0.05$) between the malignant and benign thyroid tissues.

relative gene expression data. GAPDH was used as an endogenous control, and T12 was chosen as an arbitrary calibrator sample. Gene expression profiles for TaqMan[®] PCR were plotted in conjunction with those for microarray results in Fig. 2. Pearson co-efficient was used to directly compare data from microarray analysis and TaqMan[®] RT-PCR. Table 3 depicts genes differentially expressed in both benign vs malignant and FVPTC vs classic morphology PTC.

Discussion

The primary aim of this study was to generate an overview of molecular markers of malignancy in PTC with a view to identifying discriminators between common sub-types (classic PTC and FVPTC), using genome-wide expression microarray technology validated by TaqMan[®] RT-PCR. To this end, lesions that were well characterized histologically were selected.


The application of microarray analysis designed to identify transcripts strongly associated with each group of interest yielded a gene list of 173 genes that were differentially expressed between cohorts. Significant down-regulation of Coxsackie virus receptor was recorded in the malignant cohort of thyroid lesions. The Coxsackievirus B and adenovirus receptor (CAR) plays a dual role as a homotypic junctional adhesion protein and as a viral receptor. It is biologically plausible that altered expression may impact on the morphology peculiar to PTC given its association with cellular adhesion. CAR has been shown to be differentially expressed in various human adenocarcinomas, and differential expression may represent a new factor in thyroid tumorigenesis [27].

Rab 23 expression was also down regulated in the malignant cohort. The Rab small G protein family is composed of approximately 40 members. Many of them are ubiquitous and are expressed and participate in transport processes, such as endocytosis and exocytosis [26]. Other gene targets demonstrating significant down-regulation in the malignant group were syndecans 2 and 3. Syndecans are transmembrane proteoglycans expressed on adherent cells. Changes in syndecan expression have been postulated to influence cell adhesion, migration, and the structure of focal contacts and the cytoskeleton [8].

The abundance of metallothionein genes in the cohort of genes down-regulated in PTC is interesting partly because of the sheer number of isoforms detected (Table 2). There have been many studies showing increased metallothionein expression in a plethora of cancer types but few showing decreased expression [4, 7, 33]. Although previous microarray experiments showed metallothionein genes to be down-regulated in thyroid tumours to a certain extent [2, 9, 16], none have detected so many as the current study.

Apart from microarray experiments, there has been little reported in the literature regarding metallothioneins in thyroid cancer. An early report by Nartey et al. [31] showed metallothioneins to be expressed actively in certain human thyroid neoplastic tissues but not in normal thyroid tissue, which would seem to contradict the current authors' findings. In contrast to this, a later immunohistochemical study showed an absence of metallothionein expression in 13 of 20 PTCs [36]. Interestingly, in three of the seven positive PTCs, metallothionein positivity was restricted to areas of follicular differentiation. In one of the only recent studies, Huang et al. [17] followed up their initial microarray experiment by showing that MT1G is down regulated in PTC via hypermethylation. The biological significance

Fig. 1 Hierarchical clustering of samples. This heat map shows the clustering of the 25 samples based on the 236 probes found to be differentially regulated in benign vs malignant thyroid tissue. Clustering was performed using the unweighted pair group method with arithmetic mean, with Euclidian distance as the similarity measure. Average value was used as the ordering function



of low metallothionein expression in thyroid tumours is therefore still poorly understood; however, it is interesting to speculate that metallothioneins may have roles as tumour suppressors in thyroid carcinoma.

Many genes identified, such as *LGALS3* [9, 16, 20], *LYN* [46], *TFF3* [2, 9, 16], *CRABP1* [9, 16], *BAX* [2], *MAPK4* [28], *CD44* [16], *TIMP1* [20], *FGFR2* [9], and *S100A11* [20, 40], have been previously reported in both microarray and conventional experiments in thyroid cancer. The data generated in this study corroborates the importance of several biological processes in the progression of thyroid neoplasia. For example, *S100A11* expression was up regulated in the PTC cohort compared with benign lesions, paralleling the increased protein expression of this gene target identified at the protein level using immunohistochemistry [29]. *S100A11* has also been suggested as a biomarker of malignancy in the context of colorectal carcinoma as long ago as 1995 [41].

Correlation of highlighted features with the current state of knowledge of the molecular pathology of thyroid neoplasia goes some way towards providing an external validation of the data obtained from the AB1700 system. However, additional validation using TaqMan[®] RT-PCR was performed.

In general, microarray and TaqMan[®] data correlated well with approx. 80% of comparisons having $p < 0.05$. Candidate genes were selected contingent on results identified as over-represented biological processes (oncogenesis, cell cycling, DNA replication, and homeostasis) using the Panther binomial statistics tool as opposed to the more traditional method of selecting the most highly dysregulated genes. This may account for the poor correlation observed with certain genes. Some genes, such as *TFF3* and *FGFR2*, had excellent correlation between microarray and TaqMan[®] results, whereas others, such as *BAX* and *TSHR*, showed poor correlation despite previous studies implicating them




Fig. 2 TaqMan® PCR validation of microarray experiments. Profile charts of gene expression levels comparing results obtained by microarray analysis ($n=25$) to TaqMan® PCR analysis ($n=20$) for six genes. Plots for those genes with multiple probes are also displayed where appropriate

in thyroid cancer [15, 38]. Where there was discordance in the data, it could be accounted for by differences in the sequences targeted by the TaqMan® target sequences and the microarray probe. In those cases, the array and pre-designed TaqMan assays interrogated different exons or alternative splice variants. This finding highlights the importance of matching the targets to be validated from microarray data sets.

Analysis of differentially expressed transcripts in the FVPTC revealed many transcripts showing similar expression level patterns in both FVPTC and classic morphology PTC. Examples of these transcripts are included in Table 2. In addition, somewhat surprisingly, unsupervised clustering of all samples showed no tendency for FVPTC to cluster independently of classic morphology PTC, emphasizing the very close relationship of these PTC variants (data not shown). However, analysis of differentially expressed genes in FVPTC exclusive of those identified in classic morphology PTC revealed 15 genes exhibiting differential expression in FVPTC compared with benign lesions and

conditions outwith of classic morphology PTC. These genes displayed a narrow gamut of function represented by the transcripts involved (Table 3). TaqMan® RT-PCR was performed for all of these targets to confirm the array findings and correlation with the array data was strong (see Table 3).

Aberrant expression of two major groups of transcripts was noted in FVPTC. Relatively increased expression of class 1 major histocompatibility complex (MHC) genes (HLA-A) and aberrant expression of class 2 MHC genes (HLA-DMA, HLA-DPB-1, HLA-DQB-1, HLA-DRA) and associated genes (e.g. CD74 represents the invariant membrane bound moiety of class II HLA molecules and regulates the biology and functions of MHC class II molecules and CD14 is a surface marker of monocytes/macrophages) were the most significant findings. Additionally, relatively up-regulated expression of members of the cathepsin family (cathepsin C, cathepsin H, cathepsin S, and TDO2) was striking in the FVPTC group. HLA expression is generally associated with immune functions

Table 3 Correlation between TaqMan® and microarray data

Gene	Pearson's <i>r</i> coefficient	two-tailed <i>p</i>
Genes differentially expressed in FVPTC vs classic PTC		
CD14	0.83	<0.0001
CD74 ^a	0.87	<0.0001
	0.74	0.0002
CTSC	0.53	0.0170
CTSH	0.71	0.0005
CTSS	0.62	0.0037
DPP6	0.76	0.0001
ETHE1	0.30	0.2008
HLA-A	0.77	<0.0001
HLA-DMA	0.75	0.0001
HLA-DPB1	0.96	<0.0001
HLA-DQB1 ^a	0.70	0.0006
	0.63	0.0031
HLA-DRA	0.82	<0.0001
NONAME	-0.02	0.9323
OSTF1	0.15	0.5171
TDO2	0.68	0.0009
Genes differentially expressed in benign vs malignant		
BAX	0.20	0.3997
CAMK1	0.17	0.4771
CD44	0.57	0.0094
CTSS	0.62	0.0037
CXADR	0.36	0.1152
FGFR2	0.84	<0.0001
GALE	0.54	0.0138
ICAM1	0.62	0.0038
LYN	0.45	0.0483
MAPK4	0.76	<0.0001
MMP14	0.36	0.1175
MT1F	0.92	<0.0001
MT1K ^a	0.68	0.0011
	0.69	0.0007
	0.70	0.0006
MT1X ^a	0.88	<0.0001
	0.88	<0.0001
RAB23	0.70	0.0006
S100A11	0.61	0.0041
SDC2	0.34	0.1415
SDC3	0.57	0.0087
TFF3 ^a	0.97	<0.0001
	0.96	<0.0001
TGFB1	0.56	0.0098
TIMP1	0.73	0.0003
TIMP4	0.80	<0.0001
TOP2A	0.07	0.7769
TSHR	0.18	0.4440

Gene expression profiles for TaqMan® PCR and microarray results were compared using the Pearson coefficient.

^a Genes have more than one probe ID on microarray

such as T cell interaction and antigen presentation. The presence of prominent HLA transcript expression, especially among class 2 in FVPTC, is intriguing. One potential cause of this was that tumour-infiltrating leucocytes were

responsible for this finding. However, haematoxylin–eosin (H&E)-stained slides of each case were reviewed to specifically identify the degree of tumour infiltration by leucocytes. Although a mild lymphocytic infiltrate was noted in some cases, there was no apparent over representation of lymphocytes in the follicular variant compared to benign lesions and classic morphology PTC. This raises the clear possibility that the findings represent aberrant increased expression of class 2 HLA transcripts by the epithelium of FVPTC. This is an unexpected finding, as over-expression of MHC class 2 molecules would be expected to increase tumour immunogenicity. A similar aberrant expression of HLA transcripts has been recently described in ovarian neoplasms [34]. Rangel et al. [34] concluded over-expression of HLA-DRA might represent a novel biomarker for malignancy, and this also seems biologically plausible in the FVPTC setting. A recent paper has also described HLA-DRA expression in ret/PTC-activated papillary thyroid carcinoma but not in surrounding normal thyroid follicles [19]. Yu et al. [47] showed discordant expression of (CD74li) and HLA-DR in Hashimoto thyroiditis, an autoimmune condition associated with increased incidence of PTC and sharing molecular features such as ret/PTC expression [18, 37]. Hwang et al. [19] have drawn attention to aberrant expression of HLA-DRA in ret/PTC-activated PTC. Expression of HLA-DRA may in some way explain the propensity for PTC to metastasize to lymph nodes and often apparently reside there without markedly worsening prognosis.

Cathepsins C (dipeptidyl-peptidase I), H, and S showed up-regulation in FVPTC compared to benign lesions. Cathepsins are a family of proteases that play an important role in protein degradation. They are key players in the proliferative, invasive, and metastatic potential of malignant tumour cells. Their expression in the relatively biologically indolent FVPTC is intriguing, and it remains possible that cathepsins have cellular roles outside of those involved in invasion and dissemination of tumour cells as indeed has been suggested by others [43]. For example, cathepsin L has recently been shown to play a role in nuclear transcriptional activation, and cathepsins are now recognized to play a role in MHC class II antigen presentation [44]. OSTF1 has no defined role in carcinogenesis, although outside of its role in ossification, it is also known to have roles in signal transduction and protein binding, which may be relevant to carcinogenesis and, particularly, FVPTC. A recent paper highlights the role of bone mineralization proteins including osteopontin and osteoclast stimulating factors as potential biomarkers of malignant tumours in general [1]. Indeed, in addition to elevated OSTF1 expression, increased expression of osteopontin was seen in PTC (data not shown); however, in our data, osteopontin does not appear to be specifically up-regulated

in FVPTC, and this finding has also been noted by other researchers [14]. In any case, osteopontin is known to be a downstream effector of ret/PTC [5] and mutated BRAF [14], where it acts in association with CD44, another transcript showing increased expression in both classic morphology PTC and FVPTC.

A particular focus of this study was to compare transcriptome profiles for PTCs with classic morphology and FVPTC given the propensity for FVPTC lesions to prove problematic from a diagnostic perspective. Although the study confirms the close relationship between the two most common variants of PTC, a narrow portfolio of genes and, in particular, gene functions was elucidated in the FVPTC cohort. The targets identified are easily amenable to analysis by more established techniques such as TaqMan® RT-PCR, with associated potential as additional markers for application in the FNAC setting. Clearly, the potential biomarkers identified in this study will require prospective evaluation in the context of real clinical diagnostic situations in the future to consolidate their merit as adjunctive tests in the diagnostic setting and to validate their altered expression states in the pathobiology of PTC development.

Acknowledgement Dr. Smyth and Dr. Finn contributed equally to this study.

References

- Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. *Cancer Res* 264:844–856
- Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey TJ 3rd (2003) Classification of follicular thyroid tumors by molecular signature: results of gene profiling. *Clin Cancer Res* 9:1792–1800
- Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. *Ann Stat* 29:1165–1188
- Cai L, Wang GJ, Xu ZL, Deng DX, Chakrabarti S, Cherian MG (1998) Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. *Anticancer Res* 18:4667–4672
- Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoff M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M (2004) Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. *Oncogene* 23:2188–2196
- Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ (2004) A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. *J Clin Invest* 113:1234–1242
- Deng DX, Chakrabarti S, Waalkes MP, Cherian MG (1998) Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. *Histopathology* 32:340–347
- Ding K, Lopez-Burks M, Sanchez-Duran JA, Korc M, Lander AD (2005) Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. *J Cell Biol* 171:729–738
- Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. *J Clin Endocrinol Metab* 89:3214–3223
- Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd (2004) Discrimination of benign and malignant thyroid nodules by molecular profiling. *Ann Surg* 240:425–436
- Finn SP, Smyth P, O'Leary J, Sweeney EC, Sheils O (2003) Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. *J Clin Endocrinol Metab* 88:938–941
- Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G, Vecchio G (1987) A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. *Nature* 328:170–172
- Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell* 60:557–563
- Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M (2005) Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. *J Clin Endocrinol Metab* 90:5270–5278
- Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dorken B, Daniel PT (2001) Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. *Int J Cancer* 92:805–811
- Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. *Proc Natl Acad Sci USA* 98:15044–15049
- Huang Y, de la Chapelle A, Pellegata NS (2003) Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. *Int J Cancer* 104:735–744
- Hunt JL, Baloch ZW, Barnes L, Swalsky PA, Trusky CL, Sesatomi E, Finkelstein S, LiVolsi VA (2002) Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. *Endocr Pathol* 13:321–330
- Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M (2004) Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. *Mol Endocrinol* 18:2672–2684
- Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. *Cancer Res* 65:1587–1597
- Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res* 63:1454–1457
- Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. *J Clin Endocrinol Metab* 89:4267–4271

23. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 25:402–408
24. Lloyd R, DeLellis R, Heitz P, Eng C (eds) (2004) *Pathology and genetics of tumours of endocrine Organs*. IARC Press
25. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. *Am J Surg Pathol* 28:1336–1340
26. Marcos I, Borrego S, Antinolo G (2003) Molecular cloning and characterization of human RAB23, a member of the group of Rab GTPases. *Int J Mol Med* 12:983–987
27. Marsee DK, Vadysirack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT, Jhiang SM (2005) Variable expression of Coxsackie–adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. *Thyroid* 15:977–987
28. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK (2004) Using gene expression profiling to differentiate benign versus malignant thyroid tumors. *Cancer Res* 64:2898–2903
29. Mitselou A, Vougiouklakis TG, Peschos D, Dallas P, Boumba VA, Agnantis NJ (2002) Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions. *Anticancer Res* 22:1777–1780
30. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. *J Clin Endocrinol Metab* 88:4393–4397
31. Nartey N, Cherian MG, Banerjee D (1987) Immunohistochemical localization of metallothionein in human thyroid tumors. *Am J Pathol* 129:177–182
32. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. *Cancer Lett* 209:1–6
33. Ofner D, Maier H, Riedmann B, Bammer T, Rumer A, Winde G, Bocker W, Jasani B, Schmid KW (1994) Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. *Virchows Arch* 425:491–497
34. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ (2004) Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. *Cancer Biol Ther* 3:1021–1027
35. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, Peix JL, Paulin C, Fabien N, Vecchio G, Jenkins RB, Fusco A (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. *J Clin Invest* 89:1517–1522
36. Schmid KW, Greeff M, Hittmair A, Totsch M, Ofner D, Dockhorn-Dworniczak B, Bocker W, Jasani B (1994) Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9. *Endocr Pathol* 5:114–122
37. Sheils OM, O’Leary JJ, Uhlmann V, Lattich K, Sweeney EC (2000) ret/PTC-1 activation in Hashimoto thyroiditis. *Int J Surg Pathol* 8:185–189
38. Sheils OM, Sweeney EC (1999) TSH receptor status of thyroid neoplasms–TaqMan RT-PCR analysis of archival material. *J Pathol* 188:87–92
39. Smyth P, Finn S, Cahill S, O’Regan E, Flavin R, O’Leary JJ, Sheils O (2005) ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. *Int J Surg Pathol* 13:1–8
40. Stolf BS, Abreu CM, Mahler-Araujo MB, Dellamano M, Martins WK, de Carvalho MB, Curado MP, Diaz JP, Fabri A, Brentani H, Carvalho AF, Soares FA, Kowalski LP, Hirata R Jr, Reis LF (2005) Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas. *Cancer Lett* 227:59–73
41. Tanaka M, Adzuma K, Iwami M, Yoshimoto K, Monden Y, Itakura M (1995) Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and Northern blot analysis. *Cancer Lett* 89:195–200
42. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M, Vecchio G (1999) High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. *J Clin Endocrinol Metab* 84:4232–4238
43. Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. *Biochim Biophys Acta* 1477:98–111
44. Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Dumenil AM, Riese RJ, Roth W, Saftig P, Shi GP, Chapman HA, Peters C, Ploegh HL (1999) Proteases involved in MHC class II antigen presentation. *Immunol Rev* 172:109–120
45. Williams ED (2000) Two proposals regarding the terminology of thyroid tumors. *Int J Surg Pathol* 8:181–183
46. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K (2004) Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. *Clin Cancer Res* 10:2035–2043
47. Yu M, Xu M, Savas L, Khan A (1998) Discordant expression of Ii and HLA-DR in thyrocytes: a possible pathogenetic factor in Hashimoto’s thyroiditis. *Endocr Pathol* 9:201–208